TUSTIN, Calif., March 13, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming CDMO industry conferences. These include KNect365 Life Sciences’ BioProcess International West 2018, being held March 19-22, 2018 in San Francisco, CA, and DCAT Week 2018, being held March 19-22, 2018 in New York, NY.
Details of these activities are as follows:
KNect365 Life Sciences' BioProcess International West:
Avid will host corporate booth #415 showcasing the company’s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services. Company representatives will provide a virtual tour of Avid’s 40,000 square foot state-of-the-art commercial biomanufacturing suite (Myford facility). The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into the facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.
DCAT Week:
Avid representatives will also be onsite at DCAT Week, an event hosted by the Drug, Chemical & Associated Technologies Association (DCAT). In addition to participating in related networking events, the company is hosting a table at the DCAT Annual Dinner on Thursday, March 22.
For additional details on these events, please visit: https://lifesciences.knect365.com/bpi-west/ and https://dcatweek.org/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]


Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Anta Sports Expands Global Footprint With Strategic Puma Stake
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



